EPS for bluebird bio, Inc. (BLUE) Expected At $-2.81

October 14, 2018 - By Marguerite Chambers

bluebird bio, Inc. (NASDAQ:BLUE) LogoInvestors sentiment increased to 1.4 in 2018 Q2. Its up 0.41, from 0.99 in 2018Q1. It improved, as 36 investors sold bluebird bio, Inc. shares while 69 reduced holdings. 49 funds opened positions while 98 raised stakes. 51.83 million shares or 0.73% more from 51.45 million shares in 2018Q1 were reported.
Amer Century Cos invested in 0.03% or 192,331 shares. Moreover, Winfield Assocs has 0.29% invested in bluebird bio, Inc. (NASDAQ:BLUE). Moreover, Cwm Limited Liability has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE). The Switzerland-based Gam Holding Ag has invested 0.19% in bluebird bio, Inc. (NASDAQ:BLUE). Strs Ohio holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 1,154 shares. Baker Bros Lp holds 0.24% or 200,000 shares. Los Angeles Mngmt Equity has 135,086 shares for 0.12% of their portfolio. Congress Asset Mgmt Communications Ma has 0.01% invested in bluebird bio, Inc. (NASDAQ:BLUE). California State Teachers Retirement Sys, a California-based fund reported 78,552 shares. Advisory Svcs Net Limited Com reported 0% stake. State Of Alaska Department Of Revenue holds 5,790 shares or 0.02% of its portfolio. Armistice Cap Lc invested in 180,000 shares. Savings Bank Of Montreal Can holds 0% or 29,591 shares. 11,168 are held by Kbc Nv. First Light Asset Management Ltd Liability Company has 33,360 shares.

Analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to report $-2.81 EPS on November, 7.They anticipate $1.08 EPS change or 62.43 % from last quarter’s $-1.73 EPS. After having $-2.91 EPS previously, bluebird bio, Inc.’s analysts see -3.44 % EPS growth. The stock decreased 0.43% or $0.55 during the last trading session, reaching $126.09. About 717,422 shares traded or 7.98% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 15.36% since October 14, 2017 and is uptrending. It has underperformed by 0.26% the S&P500.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 8 analysts covering Bluebird Bio (NASDAQ:BLUE), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Bluebird Bio had 12 analyst reports since May 2, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of BLUE in report on Thursday, May 3 with “Outperform” rating. The firm has “Buy” rating given on Friday, June 1 by BTIG Research. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Outperform” rating by Evercore on Tuesday, June 19. The stock has “Buy” rating by BTIG Research on Wednesday, May 2. PiperJaffray reinitiated the shares of BLUE in report on Thursday, May 31 with “Overweight” rating. The company was maintained on Wednesday, May 2 by Oppenheimer. Cantor Fitzgerald maintained bluebird bio, Inc. (NASDAQ:BLUE) rating on Sunday, June 3. Cantor Fitzgerald has “Sell” rating and $12200 target. Piper Jaffray initiated bluebird bio, Inc. (NASDAQ:BLUE) on Wednesday, May 30 with “Buy” rating. Bernstein maintained the stock with “Hold” rating in Monday, May 7 report. The firm has “Buy” rating by BTIG Research given on Friday, June 15.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington. The company has market cap of $6.83 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ??-thalassemia, and severe sickle cell disease. It currently has negative earnings. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 21, 2018, also Streetinsider.com with their article: “bluebird bio (BLUE) Granted EMA Approval for Marketing Authorization of LentiGlobin Gene Therapy” published on October 05, 2018, Seekingalpha.com published: “Orchard Rx files for IPO of American shares” on October 04, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Fool.com and their article: “Here’s Why bluebird bio Dropped 13.3% in September” published on October 11, 2018 as well as Fool.com‘s news article titled: “Why bluebird and Celgene Should Worry About Amgen’s Latest Clinical Victory” with publication date: September 14, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.